The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas1
Open accessAbstract
The natural course of adrenal incidentalomas and the risk that such lesions evolve toward hormonal hypersecretion or malignancy are still under evaluation. Of 246 consecutive patients with adrenal incidentaloma studied at our institution in the last 15 yr, 91 underwent surgery. Of the remaining patients, a group of 75 (52 females and 23 males; median age, 56 yr; range, 19–77 yr) with incidentally discovered asymptomatic adrenal masses (60 unilateral and 15 bilateral; median diameter, 2.5 cm; range, 1.0–5.6) was enrolled in an endocrine and morphological follow-up of at least 2 yr after diagnosis (median, 4 yr; range, 2–10). During follow-up, no patients developed malignancy; 9 showed mass enlargement, with appearance of a new mass in the contralateral gland in 2; 3 developed adrenal hyperfunction (overt Cushing’s syndrome in 2, nonclinical hypercortisolism in 1); and 3 showed adrenal mass enlargement associated with adrenal hyperfunction (nonclinical hypercortisolism in 2, pheochromocytoma in 1). The estimated cumulative risks to develop mass enlargement and hyperfunction were 8% and 4%, respectively, after 1 yr, 18% and 9.5% after 5 yr, and 22.8% and 9.5% after 10 yr. Nine risk factors for adrenal mass enlargement or hyperfunction were arbitrarily selected and evaluated: sex, age, presence of obesity, hypertension, diabetes, abnormal endocrine tests, mass size, mass location, and scintigraphic uptake pattern. Three of them attained statistical significance: mass size of 3 cm or more at diagnosis and exclusive radiocholesterol uptake by the mass at scintigraphy had relevance for the occurrence of adrenal hyperfunction, whereas the presence of endocrine test abnormalities at diagnosis had predictive value for mass enlargement. It is concluded that subtle hormonal abnormalities are risk factors for mass size increase, which is not a sign of malignant transformation. Both mass size of 3 cm or more at diagnosis and exclusive radiocholesterol uptake, indicating higher risks of hyperfunction, should be considered to plan a more thorough endocrine follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Incidentally Discovered Adrenal Masses*
KLOOS, R. T., GROSS, M. D., FRANCIS, I. R., KOROBKIN, M., & SHAPIRO, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-460 · Cited by 828
Incidentally discovered adrenal tumors: an institutional perspective.
Mf, H., Cs, G., van Heerden, J. A., Sheedy, P. F., & Dm, I. (1991) · PubMed · Cited by 356
Hormonal Evaluation of the Patient with an Incidentally Discovered Adrenal Mass
Desforges, J. F., Ross, N. S., & Aron, D. C. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232007 · Cited by 340
The Incidentally Discovered Adrenal Mass
COPELAND, P. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-6-940 · Cited by 317
Incidentally DiscoveredAdrenal Mass
Young, W., & Bancos, I. (2023) · Adrenal Disorders · doi:10.1016/b978-0-323-79285-1.00101-1 · Cited by 304
Incidentally discovered adrenal masses
Kloos, R. T. (1995) · Endocrine Reviews · doi:10.1210/er.16.4.460 · Cited by 267
Serendipitous adrenal masses: Prevalence, significance, and management
Abecassls, M., McLoughlin, M. J., Langer, B., & Kudlow, J. E. (1985) · The American Journal of Surgery · doi:10.1016/s0002-9610(85)80186-0 · Cited by 233
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
The Incidentally Discovered Adrenal Mass
Young, W. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp065470 · Cited by 1,096
A Survey on Adrenal Incidentaloma in Italy
Mantero, F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.637 · Cited by 855
Fassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
“large and 3–4% may decrease in size (57, 63, 202, 467).”
BackgroundAdrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Pheochromocytoma and Paraganglioma
Neumann, H. P. H., Young, W. F., & Eng, C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806651 · Cited by 736
Adrenal Masses: Characterization with Combined Unenhanced and Delayed Enhanced CT
Caoili, E. M., Korobkin, M., Francis, I. R., Cohan, R. H., Platt, J. F., Dunnick, N. R., & Raghupathi, K. I. (2002) · Radiology · doi:10.1148/radiol.2223010766 · Cited by 690
Prevalence and natural history of adrenal incidentalomas
Barzon, L., Sonino, N., Fallo, F., Palu, G., & Boscaro, M. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490273 · Cited by 642
Self-citationAME Position Statement on adrenal incidentaloma
Terzolo, M., Stigliano, A., Chiodini, I., Loli, P., Furlani, L., Arnaldi, G., Reimondo, G., Pia, A., Toscano, V, Zini, M., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1147 · Cited by 520
Zeiger, M. A., Thompson, G. B., Duh, Q.-Y., Hamrahian, A. H., Angelos, P., Elaraj, D., Fishman, E., Kharlip, J., Zeiger, M. A., Thompson, G. B., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.s1.1 · Cited by 499
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Young, W. F. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70122-5 · Cited by 415
Boscaro, M., Barzon, L., Fallo, F., & Sonino, N. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04172-6 · Cited by 350
Self-citationAdrenal incidentaloma: a new cause of the metabolic syndrome?
Terzolo, M., Pia, A., Alì, A., Osella, G., Reimondo, G., Bovio, S., Daffara, F., Procopio, M., Paccotti, P., Borretta, G., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8277 · Cited by 322
Cawood, T. J., Hunt, P. J., O'Shea, D., Cole, D., & Soule, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0234 · Cited by 300
Subclinical Cushing’s syndrome
Reincke, M. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70115-8 · Cited by 285
Diagnosis and Treatment of Subclinical Hypercortisolism
Chiodini, I. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2722 · Cited by 279
Hamrahian, A. H., Ioachimescu, A. G., Remer, E. M., Motta-Ramirez, G., Bogabathina, H., Levin, H. S., Reddy, S., Gill, I. S., Siperstein, A., & Bravo, E. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1627 · Cited by 266
Elhassan, Y. S., Alahdab, F., Prete, A., Delivanis, D. A., Khanna, A., Prokop, L., Murad, M. H., O'Reilly, M. W., Arlt, W., & Bancos, I. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3630 · Cited by 263
Long-term follow-up in adrenal incidentalomas: an Italian multicenter study
Morelli, V., Reimondo, G., Giordano, R., Della Casa, S., Policola, C., Palmieri, S., Salcuni, A. S., Dolci, A., Mendola, M., Arosio, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3527 · Cited by 223
Long-term follow-up study of patients with adrenal incidentalomas.
Libe, R., Dall'Asta, C., Barbetta, L., Baccarelli, A., Beck-Peccoz, P., & Ambrosi, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470489 · Cited by 215
Management of adrenocortical carcinoma
Allolio, B., Hahner, S., Weismann, D., & Fassnacht, M. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01881.x · Cited by 214
“The role of mitotane as adjuvant therapy after complete surgical removal of ACC remains a matter of debate (Venkatesh et al., 1989; Icard et al., 1992; Khorram-Manesh et al., 1998; Barzon et al., 1999; Kasperlik-Zaluska, 2000).”
BackgroundSubclinical Cushing’s syndrome in adrenal incidentalomas
Terzolo, M., Bovio, S., Reimondo, G., Pia, A., Osella, G., Borretta, G., & Angeli, A. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.008 · Cited by 179
Development of overt Cushing’s syndrome in patients with adrenal incidentaloma
Barzon, L., Fallo, F., Sonino, N., & Boscaro, M. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460061 · Cited by 162
“Part of the patient population was described in previous studies ( 3 , 10).”
BackgroundMethodSelf-citationAdrenal incidentaloma—follow-up results from a Swedish prospective study.
Bülow, B., Jansson, S., Juhlin, C., Steen, L., Thorén, M., Wahrenberg, H., Valdemarsson, S., Wängberg, B., Ahréen, B., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02110 · Cited by 124
Bülow, B., Ahrén, B., & the Swedish Research Council Study Group of Endocrine Abdominal Tumours (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01028.x · Cited by 120
Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study
Vassilatou, E., Vryonidou, A., Michalopoulou, S., Manolis, J., Caratzas, J., Phenekos, C., & Tzavara, I. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03492.x · Cited by 112
Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications.
Tsagarakis, S., Vassiliadi, D., & Thalassinos, N. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344133 · Cited by 113
EMRAL, R., UYSAL, A. R., ASIK, M., GULLU, S., CORAPCIOGLU, D., TONYUKUK, V., & ERDOGAN, G. (2003) · Endocrine Journal · doi:10.1507/endocrj.50.399 · Cited by 104
Bernini, G., Moretti, A., Iacconi, P., Miccoli, P., Nami, R., Lucani, B., & Salvetti, A. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480213 · Cited by 105
Giordano, R., Marinazzo, E., Berardelli, R., Picu, A., Maccario, M., Ghigo, E., & Arvat, E. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0957 · Cited by 99
Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors
Barzon, L., Chilosi, M., Fallo, F., Martignoni, G., Montagna, L., Palu, G., & Boscaro, M. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450207 · Cited by 94
Yanase, T., Oki, Y., Katabami, T., Otsuki, M., Kageyama, K., Tanaka, T., Kawate, H., Tanabe, M., Doi, M., Akehi, Y., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej17-0456 · Cited by 90
Bernini, G. P., Moretti, A., Oriandini, C., Bardini, M., Taurino, C., & Salvetti, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602459 · Cited by 87
“Barzon et al (1999), in the most comprehensive study to date, reported that though the risk of malignancy was very low even in the case of an increment in mass size, the large incidentalomas should be carefully followed-up due to the elevated probability of hyperfunction which, in their study,…”
BackgroundInfluentialManagement of incidentally discovered adrenal masses and risk of malignancy
Favia, G., Lumachi, F., Basso, S., & D'Amico, D. F. (2000) · Surgery · doi:10.1067/msy.2000.109965 · Cited by 87
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Mantero, F., & Arnaldi, G. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70119-5 · Cited by 83
Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas.
Valli, N., Catargi, B., Ronci, N., Vergnot, V, Leccia, F., Ferriere, J., Chene, G., Grenier, N., Laurent, F., & Tabarin, A. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440401 · Cited by 83
Sereg, M., Szappanos, Á., Tőke, J., Karlinger, K., Feldman, K., Kaszper, É., Varga, I., Gláz, E., Rácz, K., & Tóth, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0707 · Cited by 81
Subclinical Cushing's syndrome.
Terzolo, M., Reimondo, G., Bovio, S., & Angeli, A. (2004) · Pituitary · doi:10.1007/s11102-005-4024-6 · Cited by 80
Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma
Francucci, C. M., Pantanetti, P., Garrapa, G. G., Massi, F., Arnaldi, G., & Mantero, F. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01602.x · Cited by 65
Pros and cons of screening for occult Cushing syndrome
Tabarin, A., & Perez, P. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.51 · Cited by 57
“Although limited, the literature concerning the follow-up of SCSAs suggests that only a minority of patients will develop overt Cushing syndrome (at least in the mid term) and that in most patients the intensity of biological hypercortisolism does not progress over time”
BackgroundThe natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation.
Grossrubatscher, E., Vignati, F., Possa, M., & Loli, P. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343941 · Cited by 52
Adrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment.
Mazzuco, T. L., Bourdeau, I., & Lacroix, A. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832b7043 · Cited by 48
Ceccato, F., Antonelli, G., Frigo, A. C., Regazzo, D., Plebani, M., Boscaro, M., & Scaroni, C. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0644-8 · Cited by 44
Self-citationAnalysis of Insulin Sensitivity in Adipose Tissue of Patients with Primary Aldosteronism
Urbanet, R., Pilon, C., Calcagno, A., Peschechera, A., Hubert, E.-L., Giacchetti, G., Gomez-Sanchez, C., Mulatero, P., Toffanin, M., Sonino, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0097 · Cited by 38
Self-citationAssessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses
Yozamp, N., & Vaidya, A. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101491 · Cited by 33
Chiodini, I., Ramos-Rivera, A., Marcus, A. O., & Yau, H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2018-00382 · Cited by 25
“Because progression to overt Cushing syndrome is relatively rare [6, 7], these patients are often described separately as having “subclinical Cushing syndrome.”
BackgroundBarzon, L., Maffei, P., Sonino, N., Pilon, C., Baldazzi, L., Balsamo, A., Del Maschio, O., Masi, G., Trevisan, M., Pacenti, M., et al. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03346358 · Cited by 24
Maehana, T., Tanaka, T., Itoh, N., Masumori, N., & Tsukamoto, T. (2012) · Indian Journal of Urology · doi:10.4103/0970-1591.98461 · Cited by 13
Metadata
- Authors
- Barzon, L., Scaroni, C., Sonino, N., Fallo, F., Paoletta, A., & Boscaro, M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-02-01
- Volume
- 84
- Issue
- 2
- Pages
- 520-526
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2156424024
- Cited by
- 254
- References
- 35
- FWCI
- 16.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.